RHA® 3

Natural volume for the lips and the dynamic wrinkles and folds around them1

TEOXANE RHA 3

BEFORE

AFTER

Lip and dynamic wrinkles & folds treatment

Results that last up to 15 months in dynamic wrinkles and folds*1

Patient was treated with 1.8 mL of RHA® 3 for correction of nasolabial folds and 0.5 mL of RHA® 3 in the oral commissures. Images captured before and two weeks after treatment. Results may vary.

May be appropriate for patients who desire:

  • Enhanced fullness and contour in the lips
  • Correction for areas such as marionette lines and oral commissures1

*Clinical effectiveness and safety were demonstrated in a 15-month clinical trial for the treatment of moderate to severe nasolabial folds.1,2

Explore more results

RHA® 3

Indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults aged 22 years or older.1

Indicated for injection into the vermillion body, vermillion border, and oral commissures to achieve lip augmentation and lip fullness, in adults aged 22 years or older.1

Teoxane RHA® Collection

RHA Redensity packaging with syringe

RHA Redensity®

Fine-tuned finish

for moderate to severe dynamic perioral rhytids.1

Learn more
RHA 2 packaging with syringe

RHA® 2

Elegant softening

for moderate to severe dynamic wrinkles and folds.1

Learn more
RHA Dynamic Volume packaging with syringe

RHA® Dynamic Volume

Support and contour

for midface volume loss or correction, and moderate to severe dynamic wrinkles and folds.1

Learn more
Explore RHA®

Contact us today to become a Teoxane RHA® Collection provider.

Become a provider

RHA® Collection of Fillers, by Teoxane

Indications

The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4 with lidocaine and RHA Redensity® Mepi, RHA® 2 Mepi, RHA® 3 Mepi and RHA® Dynamic Volume, with mepivacaine.


RHA Redensity® and RHA Redensity® Mepi are indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 and...

The Teoxane RHA® Collection includes hyaluronic acid (HA) fillers with lidocaine and mepivacaine. Revance will only distribute the Teoxane RHA® Collection with mepivacaine, thus may refer to the products without the use of "Mepi" in the product name. The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine, and mepivacaine has shown no significant impact on gel properties, including rheology and degradation profile.


PLEASE SEE FULL DIRECTIONS FOR USE

RHA® Collection of Fillers, by Teoxane

Indications

The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4 with lidocaine and RHA Redensity® Mepi, RHA® 2 Mepi, RHA® 3 Mepi and RHA® Dynamic Volume, with mepivacaine.

RHA Redensity® and RHA Redensity® Mepi are indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 and RHA® 2 Mepi are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) in adults 22 or older. RHA® 3 and RHA® 3 Mepi are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) and is also indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) in adults 22 or older. RHA® Dynamic Volume is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) and for injection into the subcutaneous to supraperiosteal layers for cheek augmentation and/or correction of age-related midface contour deficiencies in adults 22 or older.


IMPORTANT SAFETY INFORMATION

Contraindications

Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine and mepivacaine.

Do not use in patients with bleeding disorders.

Warnings

Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures.

Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur.

Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

Precautions

These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies
As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.

The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.
Use with caution in patients on immunosuppressive therapy.

Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites.

Patients with a history of herpetic eruptions may experience reactivation of the herpes.

There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment.

Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.

For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events

The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

To report an adverse event with any RHA® product to Revance, please visit Safety.Revance.com or call at 1 (877) 373-8669.

RHA® and RHA Redensity® are registered trademarks of TEOXANE SA. MLT MULTI LAYERING TECHNIQUETM is a trademark of TEOXANE SA. The Teoxane RHA® Collection is manufactured by Teoxane SA in Switzerland and exclusively distributed by Revance. All other trademarks are the property of their respective owners.

Available by Prescription only

RHA-00221

REFERENCES:

  1. RHA® Directions for Use.
  2. Monheit G, Kaufman-Janette J, Joseph JH, Shamban A, Dover JS, Smith S. Efficacy and safety of two resilient hyaluronic acid fillers in the treatment of moderate-to-severe nasolabial folds: A 64-week, prospective, multicenter, controlled, randomized, double-blinded, and within-subject study. Dermatol Surg. 2020;46(12):1521-1529.
  3. Weinkle S, Dayan SH, Draelos Z et al. Effectiveness and safety of RHA® 3 versus a comparator product for lip augmentation: a randomized, controlled, prospective, multicenter clinical study. Aesthet Surg J. 2025;45(11):1175-1186.
  4. Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Advanced concepts in rheology for the evaluation of hyaluronic acid-based soft tissue fillers. Dermatol Surg. 2021;47(5):e159-e167.
RHA® Collection, by Teoxane Logo

© Teoxane SA- All rights reserved

Provider LoginPrivacy PolicyTerms of UseHealth Data Privacy PolicyRevance.com
Products
RHA Redensity® RHA® 2 RHA® 3 RHA® Dynamic Volume
Customer Service
Follow
©2026 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA. MLT MULTI LAYERING TECHNIQUETM is a trademark of TEOXANE SA. The Teoxane RHA® Collection is manufactured by Teoxane SA in Switzerland and exclusively distributed by Revance. All other trademarks are the property of their respective owners.

RHA-01274